Kythera Biopharmaceuticals.
Throughout its history, Allergan has expanded both organically and as the result of strategic acquisitions that brought broader product lines, enhanced drug delivery technologies, and ultimately branded pharmaceutical products to the company. In June 2015 Allergan announced it would acquire Kythera Biopharmaceuticals for around $2.1 billion. On June 1, the company completed its acquisition of Auden Mckenzie Holdings Limited for £306 million. On July 6, the company acquired start-up, Oculeve, for $125 million. Ackman owns nearly 10% of Allergan's stock, and the company has already adopted a so-called poison-pill provision preventing any shareholder from acquiring more than 10% of the company, so his voting sway over Allergan's decision will not increase. On Valeant's first-quarter-earnings conference call, Pearson said he expects the company to exit 2014 with R&D spending at about a $200 million a year. Allergan argues that its R&D spending doesn't result in a bunch of wasted money. Allergan (NYSE: AGN), maker of Botox, is a global specialty pharmaceutical company that researches, develops and manufactures prescription and over the counter specialty pharmaceuticals. The share price of Allergan PLC (NYSE: AGN) has declined 17.25 percent over the past month, after having reached a high of $308.995 on August 31. WASHINGTON (dpa-AFX) - Pharmaceuticals company Allergan plc (AGN) on Friday announced a multi-year research collaboration with Humana Inc (HUM) to explore ways to improve the health and well-being of patients, members and their caregivers. The share price of Allergan PLC (NYSE: AGN) has declined 17.25 percent over the past month, after having reached a high of $308.995 on August 31. Allergan owns or is licensed under a number of patents which protect its products. Patent expiration for Allergan's eye care products are as near as 2009 for Restasis, 2012 for Alphagan P (in the US) and 2009 in Europe, 2009 for Acular and 2010 for Zymar and 2015 for Lumigan. The share price of Allergan PLC (NYSE: AGN) has declined 17.25 percent over the past month, after having reached a high of $308.995 on August 31. For these reasons, Mr. Pyott said, it would be irresponsible to sell the company for compensation consisting largely of Valeant stock. For Valeant and Pershing Square, the sale of Allergan to Actavis will not be not a total loss. Mr. Ackman’s firm owns 9.7 percent of Allergan and will profit handsomely. “Today’s transaction provides Allergan stockholders with substantial and immediate value, as well as the opportunity to participate in the significant upside potential of the combined company,” Mr. Pyott said in a statement. After seven months of bids, bluster and lawsuits, the hedge fund manager William A. Ackman and Valeant Pharmaceuticals appear to be giving up their pursuit of Allergan, the maker of Botox, as another big drug maker has trumped their hostile bid. In 1990 Allergan was close to a billion-dollar company, but its stock had fallen from $25 (at the time of its spinoff) to $15 a share. Investment analysts began to advise investors that Allergan was prime for a takeover, pointing to Nestle'nestlé S Alcon laboratories as a potential. purchaser Toward the realization of that plan, Allergan purchased 24 acres from the Irvine Ranch Company and, in 1968, built its Von Karman production facility on that site. In 1971 Allergan erected its first office building in Irvine, California, where it remained headquartered in the early 21st century. Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM® ULTRA XC for injection into the lips and perioral area... The share price of Allergan PLC (NYSE: AGN) has declined 17.25 percent over the past month, after having reached a high of $308.995 on August 31. But Actavis’s offer of $219 a share appears to put Allergan out of reach for Valeant and Pershing Square. Shares of Allergan rose $10.55, or 5.3 percent, to $209.20, still below the takeover price. After seven months of bids, bluster and lawsuits, the hedge fund manager William A. Ackman and Valeant Pharmaceuticals appear to be giving up their pursuit of Allergan, the maker of Botox, as another big drug maker has trumped their hostile bid. Allergan also operates the world's third-largest generics business and has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. In June 2015 Allergan announced it would acquire Kythera Biopharmaceuticals for around $2.1 billion. On June 1, the company completed its acquisition of Auden Mckenzie Holdings Limited for £306 million. On July 6, the company acquired start-up, Oculeve, for $125 million.
https://en.wikipedia.org/wiki/Allergan http://www.businessinsider.com/valeant-business-model-2014-6 http://www.wikinvest.com/stock/Allergan_(AGN) http://www.wikinvest.com/stock/Allergan_(AGN) http://www.wikinvest.com/stock/Allergan_(AGN) http://dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/ http://www.referenceforbusiness.com/history2/51/Allergan-Inc.html http://www.wikinvest.com/stock/Allergan_(AGN) http://dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/ https://en.wikipedia.org/wiki/Allergan
what company does allergan owns